Security Snapshot

SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) Institutional Ownership

CUSIP: 800677106

13F Institutional Holders and Ownership History from Q1 2014 to Q1 2026

Latest Period

Q4 2025

Institutions Reporting

104

Shares (Excl. Options)

62,261,277

Price

$0.42

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.

Create free account to save this page Review latest holder period
Type / Class
Equity / Common Stock
Symbol
SGMO on Nasdaq
Shares outstanding
294,683,714
Price per share
$0.25
All holders as of 31 Dec 2025
Q4 2025
Total 13F shares
62,261,277
Total reported value
$26,151,849
% of total 13F portfolios
0%
Share change
-695,945
Value change
-$866,572
Number of holders
104
Price from insider filings
$0.25
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • SGMO - SANGAMO THERAPEUTICS, INC - Common Stock is tracked under CUSIP 800677106.
  • 104 institutions reported positions in Q4 2025.
  • 1 significant owner is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 104 to 9 between Q4 2025 and Q1 2026.
  • Reported value moved from $26,151,849 to $247,061.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 104 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 800677106?
CUSIP 800677106 identifies SGMO - SANGAMO THERAPEUTICS, INC - Common Stock in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Significant Owners of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WASATCH ADVISORS LP 2.1% -62% $4,167,240 -$3,664,854 6,188,358 -47% Wasatch Advisors LP 30 Sep 2025

As of 31 Dec 2025, 104 institutional investors reported holding 62,261,277 shares of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO). This represents 21% of the company’s total 294,683,714 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) together control 20% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
VANGUARD GROUP INC 4.1% 12,000,383 +3.3% 0% $5,040,161
RENAISSANCE TECHNOLOGIES LLC 2.9% 8,430,323 -17% 0.01% $3,540,736
TWO SIGMA INVESTMENTS, LP 1.6% 4,755,995 +92% 0% $1,997,518
BlackRock, Inc. 1.6% 4,571,786 +0.34% 0% $1,920,150
TWO SIGMA ADVISERS, LP 1.5% 4,343,255 +106% 0% $1,824,167
GEODE CAPITAL MANAGEMENT, LLC 1.3% 3,866,026 +18% 0% $1,624,115
JANE STREET GROUP, LLC 0.99% 2,918,127 +33% 0% $1,225,614
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.73% 2,137,120 -12% 0% $897,590
CHARLES SCHWAB INVESTMENT MANAGEMENT INC 0.58% 1,713,331 +11% 0% $719,599
WASATCH ADVISORS LP 0.48% 1,416,717 -0.68% 0% $595,021
STATE STREET CORP 0.46% 1,355,583 0% 0% $569,345
Ikarian Capital, LLC 0.41% 1,218,671 -5.9% 0.07% $511,842
LUMINUS MANAGEMENT LLC 0.39% 1,158,761 +364% 0.45% $486,680
JACOBS LEVY EQUITY MANAGEMENT, INC 0.36% 1,050,714 +24% 0% $441,300
ORACLE INVESTMENT MANAGEMENT INC 0.35% 1,035,742 +3.1% 0.29% $435,012
UBS Group AG 0.35% 1,024,475 -22% 0% $430,280
Invesco Ltd. 0.34% 1,000,292 +24% 0% $420,123
NORTHERN TRUST CORP 0.25% 737,867 +15% 0% $309,904
HighTower Advisors, LLC 0.24% 704,456 -5.3% 0% $295,872
GROUP ONE TRADING LLC 0.17% 500,179 -0.36% 0.01% $210,075
MORGAN STANLEY 0.14% 423,752 -28% 0% $177,975
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. 0.14% 400,000 0% 0% $168,000
Golden State Equity Partners 0.13% 395,943 -5.5% 0.03% $166,296
Diametric Capital, LP 0.13% 395,332 +10% 0.04% $166,039
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 0.12% 348,038 +74% 0% $146,176

Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 985,141 $247,061 +$197,037 $0.25 9
2025 Q4 62,261,277 $26,151,849 -$866,572 $0.42 104
2025 Q3 62,601,923 $42,143,656 -$4,085,084 $0.67 112
2025 Q2 73,226,420 $39,627,128 -$1,366,580 $0.54 110
2025 Q1 52,557,554 $34,474,526 -$6,973,632 $0.66 118
2024 Q4 61,547,249 $62,817,305 +$5,840,058 $1.02 125
2024 Q3 55,892,914 $48,377,748 -$13,237,737 $0.87 100
2024 Q2 86,880,740 $31,098,958 -$5,513,248 $0.36 126
2024 Q1 100,425,667 $67,257,419 +$9,590,265 $0.67 125
2023 Q4 86,966,421 $47,198,697 -$9,265,269 $0.54 129
2023 Q3 102,314,735 $61,341,591 -$4,250,211 $0.60 131
2023 Q2 105,778,869 $137,125,383 -$10,782,201 $1.30 149
2023 Q1 112,297,853 $197,560,841 +$11,997,591 $1.76 178
2022 Q4 104,011,293 $326,153,436 +$18,050,138 $3.14 179
2022 Q3 97,395,258 $477,415,251 +$38,514,658 $4.90 189
2022 Q2 89,662,495 $371,001,039 +$44,113,066 $4.14 174
2022 Q1 79,972,857 $465,159,583 +$13,325,276 $5.81 184
2021 Q4 76,880,593 $576,854,799 +$14,652,510 $7.50 178
2021 Q3 75,230,827 $678,917,887 -$11,341,782 $9.01 182
2021 Q2 76,183,727 $911,820,230 -$39,619,833 $11.97 189
2021 Q1 79,366,997 $993,813,520 +$8,744,496 $12.53 189
2020 Q4 78,279,519 $1,221,988,081 -$2,887,670 $15.60 215
2020 Q3 81,633,901 $772,262,574 +$39,692,524 $9.45 203
2020 Q2 77,064,448 $690,282,893 +$38,360,714 $8.96 197
2020 Q1 74,003,681 $471,429,640 -$44,160,048 $6.37 175
2019 Q4 78,484,613 $656,787,904 -$35,488,595 $8.37 187
2019 Q3 82,109,589 $743,984,330 +$18,180,888 $9.05 178
2019 Q2 79,874,675 $860,158,811 +$188,076,135 $10.77 178
2019 Q1 65,891,322 $628,583,823 +$8,491,929 $9.54 178
2018 Q4 63,962,974 $734,063,851 -$24,514,588 $11.48 189
2018 Q3 64,628,739 $1,095,486,294 +$6,279,681 $16.95 214
2018 Q2 64,727,770 $919,122,586 +$101,709,560 $14.20 206
2018 Q1 57,191,865 $1,086,683,045 +$32,050,241 $19.00 205
2017 Q4 55,555,574 $911,135,543 +$36,567,117 $16.40 167
2017 Q3 54,652,539 $819,732,570 +$37,421,908 $15.00 147
2017 Q2 53,038,835 $466,764,979 +$100,856,480 $8.80 143
2017 Q1 41,889,756 $217,701,771 +$36,392,442 $5.20 115
2016 Q4 41,299,445 $125,949,665 -$12,015,817 $3.05 120
2016 Q3 43,952,613 $203,488,438 -$12,236,220 $4.63 121
2016 Q2 46,220,859 $267,610,930 -$15,550,987 $5.79 136
2016 Q1 48,689,873 $292,366,107 -$4,019,351 $6.05 142
2015 Q4 49,096,342 $448,268,385 -$26,270,998 $9.13 139
2015 Q3 52,669,346 $297,043,899 -$28,205,503 $5.64 140
2015 Q2 50,554,743 $560,557,135 -$37,822,320 $11.09 156
2015 Q1 52,645,653 $825,232,264 +$55,231,033 $15.68 167
2014 Q4 49,165,950 $747,418,239 +$7,297,640 $15.21 157
2014 Q3 48,823,503 $526,594,567 -$9,059,452 $10.78 157
2014 Q2 48,883,624 $746,320,055 -$18,445,491 $15.27 154
2014 Q1 48,216,512 $871,455,782 +$52,843,003 $18.08 144